Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
The Orange Box is a video game compilation containing five games developed and published by Valve. Two of the games included—Half-Life 2 and its first stand-alone expansion, Episode One—had previously been released in 2004 and 2006 as separate products. Three new games were also included in the compilation: the second stand-alone expansion, Half-Life 2: Episode Two; the puzzle game Portal; and Team Fortress 2, the sequel to Team Fortress Classic. Valve also released a soundtrack containing music from the games within the compilation. A separate product entitled The Black Box was planned, which would have included only the new games, but was later canceled. The Orange Box was released for Windows and the Xbox 360 in October 2007, while the PlayStation 3 version, developed by EA UK, was released in December 2007. The Xbox 360 and PlayStation 3 versions were published by Electronic Arts. A digital Orange Box pack, containing the five games, was released in May 2010 for Mac OS X following the release of Steam for the platform, while a similar version for Linux followed after the Steam's clients release for Linux in early 2013. The Orange Box received widespread critical acclaim, with Portal being recognized as a surprise favorite of the package. The PlayStation 3 version of The Orange Box, however, was criticized for containing several technical shortcomings that were not present in the other versions, only a few of which were fixed through a single patch.
== Further reading == Manna, Utpal; Sritharan, S. S. (2007). "Lyapunov Functionals and Local Dissipativity for the Vorticity Equation in Lp and Besov spaces". Differential and Integral Equations. 20 (5): 581–598. arXiv:0802.2898. doi:10.57262/die/1356039440. S2CID 50701138. Barbu, V.; Sritharan, S. S. (2000). "M-Accretive Quantization of the Vorticity Equation" (PDF). In Balakrishnan, A. V. (ed.). Semi-Groups of Operators: Theory and Applications. Boston: Birkhauser. pp. 296–303. Krigel, A. M. (1983). "Vortex evolution". Geophysical & Astrophysical Fluid Dynamics. 24 (3): 213–223. Bibcode:1983GApFD..24..213K. doi:10.1080/03091928308209066.
=== List of superintendents === Shawn Joseph (interim 2025–2026; 2026-present) Millard House II (2023–2025) Monica Goldson, CEO (interim 2018–2019; 2019–2023) Kevin M. Maxwell, CEO (2013–2018) Alvin Crawley (interim 2012–2013) William R. Hite, Jr. (interim 2008–2009; 2009–2012) John E. Deasy (2006–2008) Howard A. Burnett (interim 2005–2006) André J. Hornsby (2003–2005) Iris T. Metts (1999–2003) Jerome Clark (1995–1999) Edward M. Felegy (1991–1995) John A. Murphy (1984–1991) Edward J. Feeney (1976–1984) Carl W. Hassel (1970–1976) William S. Schmidt (1951–1970) G. Gardner Shugart (1944–1951) Nicholas Orem Sr. (1921–1943) E.S. Burroughs (1915–1921) Frederick Sasscer Jr. (1902–1914)
== Diagnosis == The diagnosis of episcleritis is based upon the history and physical examination. The history should be explored for the presence of the diseases associated with episcleritis, and the symptoms they cause, such as rash, arthritis, venereal disease, and recent viral infection. Episcleritis may be differentiated from scleritis by using phenylephrine or neosynephrine eye drops, which causes blanching of the blood vessels in episcleritis, but not in scleritis. A blue color to the sclera suggests scleritis, rather than episcleritis. After anesthetizing the eye with medication, the conjunctiva may be moved with a cotton swab to observe the location of the enlarged blood vessels. In very rare cases, if episcleritis does not respond to treatment, then a biopsy may be considered, which help provide information regarding any underlying condition (granulomatosis with polyangitis, vasculitis, etc.). However, a biopsy is not routinely necessary in the diagnosis of episcleritis.
However, the military provided him with no records of any medical discrepancies caused by actions during war. If Willie was to be diagnosed with Gulf War Illness, he would not have a course of treatment. He would have to learn to cope with the disease until a treatment becomes available in the future. Willie and his wife go to visit a Marine Veteran who was diagnosed with Gulf War Illness to be able to relate any similarities and narrow down the possibilities.
Sources: en.wikipedia.org
== See also == TACAMO Boeing EC-135 Boeing E-4 Advanced Airborne Command Post ("Nightwatch") E-6 Mercury Airborne Launch Control System Airborne Launch Control Center Decapitation strike Letters of last resort Dead Hand (Perimeter) Continuity of Operations Plan Single Integrated Operational Plan Nuclear utilization target selection
== Adaptogenic and neuroprotective effects == A neurocytological study of granular cerebellar neurons in culture under conditions of moderate glutamate stress showed that lithium ascorbate is more effective in maintaining neuronal survival than inorganic lithium salts (chloride, carbonate). Under conditions of glutamate stress, lithium ascorbate at concentrations of 0.2–1.0 mM significantly and dose-dependently increased the survival of neurons: the most pronounced neuroprotective effect was observed at an ascorbate concentration of 1 mM (by 11%). The use of lithium ascorbate even at the minimum concentration (0.1 mM) resulted in a significant difference in neuron survival (p=0.049 according to the Kolmogorov-Smirnov test). The use of a non-lithium salt of ascorbic acid (potassium ascorbate) was characterized by a much less pronounced neuroprotective effect. Inhibition of glycogen synthase kinase syntentase-3 (GSK-3) and induction of brain-derived neurotrophic factors are the main mechanisms of the neuroprotective action of lithium salts. In addition, by inhibiting NMDA receptors, lithium ions can regulate calcium homeostasis and inhibit the activation of calcium-dependent apotosis, also showing synergy with neuropeptides.
Amphetamine is also a substrate for the presynaptic vesicular monoamine transporter, VMAT2. Following amphetamine uptake at VMAT2, amphetamine induces the collapse of the vesicular pH gradient, which results in a dose-dependent release of dopamine molecules from synaptic vesicles into the cytosol via dopamine efflux through VMAT2. Subsequently, the cytosolic dopamine molecules are released from the presynaptic neuron into the synaptic cleft via reverse transport at DAT.
==== Liquid-liquid extraction ==== Liquid-liquid extractions can be carried out on digital microfluidic device by taking advantage of immiscible liquids.9 Two droplets, one containing the analyte in aqueous phase, and the other an immiscible ionic liquid are present on the electrode array. The two droplets are mixed and the ionic liquid extracts the analyte, and the droplets are easily separable.
Sources: en.wikipedia.org
=== Political activism === In 2018, she became spokesperson of the On est prêt collective. She spoke at the European Parliament, notably alongside Greta Thunberg, Belgians Adélaïde Charlier and Anuna De Wever and the German Luisa Neubauer. It was at Sciences Po Paris that Camille turned her attention to the climate crisis. She became president of the student branch of Amnesty International. She was also elected, in 2018, to the student organisation NOVA. During lockdown, she created the collective 'Avant l'orage' (Before the Storm) which aims to bring together art and environmentalism. On 28 May 2020 the collective's YouTube channel released a video titled Wake Up. The video, filmed in the mountains, features the activist with a dancer and engineering graduate, Léa Durand. Camille speaks about the climate emergency and reminds viewers, particularly those from Generation Z, on the need to act. Her words are accompanied by movements from the dancer. The video was a success, gaining 15 million views on various platforms and has been translated into Spanish, English, German and Portuguese. In August 2020, while speaking at the Medef summer school, she suggested "working less, but maybe with more meaning" to "reinvent" the world of business. She also questions the economic growth model, which, according to her, pushes us to "produce too much", "exceed planetary limits" and so "directly endangers our lives".
A familial form of pseudohyperkalemia, a benign condition characterised by increased serum potassium in whole blood stored at cold temperatures, also exists. This is due to increased potassium permeability in red blood cells.
The University Grants Committee funds eight public universities in Hong Kong. The Hong Kong Academy for Performing Arts also receives funding from the government. There are four self-financing universities, namely Hong Kong Metropolitan University, Hong Kong Shue Yan University, Hang Seng University of Hong Kong, and Saint Francis University.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.